A look at Bristol-Myers Squibb Co.
Bristol-Myers Squibb (BMY) is an American pharmaceutical company that deals with innovative medicines for patients with serious diseases in therapeutic areas including virology, oncology, cardiovascular, neuroscience, and immuno-science.
Stock price performance
Bristol-Myers Squibb’s stock price fell ~11.7% in 1Q17. On April 6, 2017, the stock’s price had risen 9.2% year-to-date (or YTD).
Analysts estimate that the stock has the potential to return ~4.4% over the next 12 months. Analysts’ recommendations show a 12-month target price of $55.41 per share, compared to the stock’s price of $53.08 per share on April 5, 2017.
There are 23 analysts tracking Bristol-Myers Squibb stock, and 43.5% of them recommend “buys,” 47.8% recommend “holds,” and 8.7% recommend “sells.” The consensus rating for Bristol-Myers Squibb is 2.4, representing a moderate “buy” for value investors and long-term growth investors.
Analysts’ revenue estimates
Bristol-Myers Squibb’s revenue has risen over the past few years following the strong performances of some of its key products such as Opdivo, Yervoy, Sprycel, and Empliciti in its oncology franchise, Orencia in its immuno-science franchise, and Eliquis in its cardiovascular franchise.
Analysts’ estimates show revenue of $4.7 billion, an 8% rise over 2016, and earnings per share (or EPS) of $0.75 for the company in 1Q17.
To divest company-specific risk, investors can consider ETFs such as the iShares U.S. Healthcare ETF (IYH), which holds 3.0% of its total assets in Bristol-Myers Squibb, 3.4% in AbbVie (ABBV), 10.8% in Johnson & Johnson (JNJ), and 3.2% in Allergan (AGN).